Tags

Type your tag names separated by a space and hit enter

The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Bipolar Disord 2015; 17(5):528-35BD

Abstract

OBJECTIVES

We tested the hypothesis that a common functional variant in brain-derived neurotrophic factor (BDNF), Val66Met, which has been shown to be associated with increased body mass index (BMI) in schizophrenia (SCZ) and schizoaffective disorder (SAD), is also associated with antipsychotic-induced weight gain in bipolar disorder (BPD). Association of Val66Met with other metabolic measures, including high- and low-density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested.

METHODS

This was a 12-month, prospective, randomized trial of two atypical antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76).

RESULTS

BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high-density (HDL) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log-triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log-triglycerides (p = 0.03) and triglycerides/HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01).

CONCLUSIONS

The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well.

Authors+Show Affiliations

Department of Psychosis Studies, Institute of Psychiatry at the Maudsley, King's College London, London, UK.Department of Pharmacy Practice, University of Illinois, Chicago, IL, USA.Department of Psychiatry and Behavioural Sciences, Northwestern University, Chicago, IL, USA.Mayo Clinic, Rochester, MN, USA.Southern Arizona VA Health Care System, Tucson, AZ, USA.Faculty of Medicine, Department of Psychiatry, Gaziosmanpasa University, Tokat, Turkey.Department of Psychosis Studies, Institute of Psychiatry at the Maudsley, King's College London, London, UK.Department of Psychiatry and Behavioural Sciences, Northwestern University, Chicago, IL, USA.Department of Psychiatry and Behavioural Sciences, Northwestern University, Chicago, IL, USA.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25874530

Citation

Bonaccorso, Stefania, et al. "The Brain-derived Neurotrophic Factor (BDNF) Val66Met Polymorphism Is Associated With Increased Body Mass Index and Insulin Resistance Measures in Bipolar Disorder and Schizophrenia." Bipolar Disorders, vol. 17, no. 5, 2015, pp. 528-35.
Bonaccorso S, Sodhi M, Li J, et al. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disord. 2015;17(5):528-35.
Bonaccorso, S., Sodhi, M., Li, J., Bobo, W. V., Chen, Y., Tumuklu, M., ... Meltzer, H. Y. (2015). The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disorders, 17(5), pp. 528-35. doi:10.1111/bdi.12294.
Bonaccorso S, et al. The Brain-derived Neurotrophic Factor (BDNF) Val66Met Polymorphism Is Associated With Increased Body Mass Index and Insulin Resistance Measures in Bipolar Disorder and Schizophrenia. Bipolar Disord. 2015;17(5):528-35. PubMed PMID: 25874530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. AU - Bonaccorso,Stefania, AU - Sodhi,Monsheel, AU - Li,Jiang, AU - Bobo,William V, AU - Chen,Yuejin, AU - Tumuklu,Mevhibe, AU - Theleritis,Christos, AU - Jayathilake,Karuna, AU - Meltzer,Herbert Y, Y1 - 2015/04/15/ PY - 2014/04/07/received PY - 2014/12/17/accepted PY - 2015/4/16/entrez PY - 2015/4/16/pubmed PY - 2016/3/10/medline KW - antipsychotic drugs KW - bipolar disorder KW - body mass index KW - brain-derived neurotrophic factor (BDNF) Val66Met KW - glucose KW - lipids KW - schizophrenia SP - 528 EP - 35 JF - Bipolar disorders JO - Bipolar Disord VL - 17 IS - 5 N2 - OBJECTIVES: We tested the hypothesis that a common functional variant in brain-derived neurotrophic factor (BDNF), Val66Met, which has been shown to be associated with increased body mass index (BMI) in schizophrenia (SCZ) and schizoaffective disorder (SAD), is also associated with antipsychotic-induced weight gain in bipolar disorder (BPD). Association of Val66Met with other metabolic measures, including high- and low-density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested. METHODS: This was a 12-month, prospective, randomized trial of two atypical antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76). RESULTS: BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high-density (HDL) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log-triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log-triglycerides (p = 0.03) and triglycerides/HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01). CONCLUSIONS: The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well. SN - 1399-5618 UR - https://www.unboundmedicine.com/medline/citation/25874530/The_brain_derived_neurotrophic_factor__BDNF__Val66Met_polymorphism_is_associated_with_increased_body_mass_index_and_insulin_resistance_measures_in_bipolar_disorder_and_schizophrenia_ L2 - https://doi.org/10.1111/bdi.12294 DB - PRIME DP - Unbound Medicine ER -